Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 20 Oct 2020
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Lorcaserin shows therapeutic potential in patients with impulsive aggressive behaviour

05 Feb 2020

The 5-HT2c receptor agonist lorcaserin has the potential to be repurposed for the treatment of impulsive aggression in humans, as shown in a pilot study.

Ten male and female adults with impulsive aggressive behaviour were randomly assigned to receive lorcaserin 20 mg or a matching placebo for 2 days separated by at least a 7-day washout. Researchers evaluated aggressive responding using the Taylor aggression paradigm, where patients competed against a fictitious opponent in a reaction time game during which electric shock was administered and received.

All participants had high aggression scores on the Life History of Aggression assessment (mean, 20.3) and the Buss-Perry Aggression questionnaire (mean, 47.6) relative to mean scores of 6.4 and 30.7, respectively, in nonaggressive participants reported in the literature.

Compared with placebo, lorcaserin mitigated provoked, but not unprovoked, aggression during the Taylor aggression paradigm. This was demonstrated by significant reductions in the mean frequency of selecting “high/extreme” shock levels against the opponent (7.30 with placebo vs 2.50 with the active drug; p=0.030).

The findings provide a rationale to conduct a double-blind clinical trial of lorcaserin in impulsively aggressive individuals to establish the potential antiaggressive effect of the drug, according to the researchers.

“[T]hat lorcaserin may have antiaggressive properties is consistent with the serotonin hypothesis of aggression that posits that agents that increase serotonergic activity will reduce impulsively aggressive behaviour,” they explained.  (Coccaro et al., 1989; Coccaro, Lee, & Kavoussi, 2010).

However, the researchers also pointed out that “as a receptor agonist, lorcaserin may work when selective serotonin reuptake inhibitors are not effective, especially in cases where postsynaptic serotonin (eg, 5-HT2c) receptors are highly downregulated.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 20 Oct 2020
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.